Gilead ex­pands its big bet on Ar­cus, mov­ing in­to in­flam­ma­tion in large new col­lab­o­ra­tion

Gilead and Ar­cus are ex­pand­ing their al­ready sig­nif­i­cant part­ner­ship, adding in­flam­ma­tion tar­gets to what was al­ready one of the biggest col­lab­o­ra­tion deals in the biotech world.

In 2020, the com­pa­nies an­nounced a 10-year agree­ment to go af­ter can­cer tar­gets that came with a $175 mil­lion up­front, a $200 mil­lion eq­ui­ty in­vest­ment and as much as $1.6 bil­lion in mile­stone pay­ments. That deal made Gilead a de­vel­op­ment and com­mer­cial part­ner on Ar­cus’s pro­grams, in­clud­ing its close­ly-watched TIG­IT can­di­date, with an op­tion to pay $150 mil­lion per mol­e­cule for fu­ture can­di­dates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER